Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Quinidine Gluconate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Quinidine Gluconate, the Mechanism of Action for Quinidine Gluconate, and the drug target R&D trends for Quinidine Gluconate.
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Drug Insights
4 min read
Unleashing the Power of Proparacaine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Proparacaine Hydrochloride, the Mechanism of Action for Proparacaine Hydrochloride, and the drug target R&D trends for Proparacaine Hydrochloride.
Valuable Targets
6 min read
Targeting 5-lipoxygenase - Leukotriene inhibitor
19 September 2023
Leukotrienes are a group of inflammatory mediators produced by the metabolism of arachidonic acid (AA) through the 5-lipoxygenase (5-LO) pathway, featuring a conjugated triene structure of a 20-carbon unsaturated acid.
Drug Insights
4 min read
A Comprehensive Review of Pralidoxime Chloride's R&D Innovations
19 September 2023
This article summarized the latest R&D progress of Pralidoxime Chloride, the Mechanism of Action for Pralidoxime Chloride, and the drug target R&D trends for Pralidoxime Chloride.
Latest Hotspot
3 min read
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
19 September 2023
Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.
Drug Insights
4 min read
Pharmaceutical Insights: Phenylpropanolamine Hydrochloride's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Phenylpropanolamine Hydrochloride, the Mechanism of Action for Phenylpropanolamine Hydrochloride, and the drug target R&D trends for Phenylpropanolamine Hydrochloride.
Valuable Targets
8 min read
Breaking the "Undruggable" Curse: A Discussion on KRAS Inhibitors
19 September 2023
As one of the three major types of genes in the RAS family, the KRAS mutation is one of the most common oncogenic mutations in cancer patients.
Drug Insights
4 min read
Exploring Phentolamine Mesylate's Revolutionary R&D Successes
19 September 2023
This article summarized the latest R&D progress of Phentolamine Mesylate, the Mechanism of Action for Phentolamine Mesylate, and the drug target R&D trends for Phentolamine Mesylate.
Latest Hotspot
3 min read
Bioscience Replication begins a Phase 1 Study for its upcoming srRNA Vaccine
19 September 2023
Replicate Bioscience has administered the first dosage of its RBI-4000 vaccine to a participant.
Drug Insights
4 min read
Decoding Norepinephrine Bitartrate: A Comprehensive Study of its R&D Trends
19 September 2023
This article summarized the latest R&D progress of Norepinephrine Bitartrate, the Mechanism of Action for Norepinephrine Bitartrate, and the drug target R&D trends for Norepinephrine Bitartrate.
Valuable Targets
6 min read
Progress in the Research of MEK Inhibitors
19 September 2023
MEK, or Mitogen-Activated Protein Kinase Kinase, plays a crucial role in the human body as a key component of the MAPK signaling pathway.